RESEARCH / DISCOVERY
← Back to the library

[Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].

[Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].

Read the original publication

A plain-language reading has not been prepared for this paper yet.

Original abstract

On the basis of reports in the literature and of our own clinical experience it appears that melanocyte inhibiting factor (MIF) is a very promising therapeutic agent in the management of Parkinson's disease. Besides theoretical considerations relating to biochemical and pathophysiological spheres, the question of the current dosage for clinical usage seems to be of the utmost importance. We are of the opinion that the currently-employed dosage of 400 mg daily is still too low. Hence, the present investigation will be continued with a view to establishing the optimum dosage for maximal therapeutic effect.

Explore another example or bring your own paper

Pasted text and PDF extraction stay on this computer. The local guide explains terms and surfaces passages; rewriting requires a configured local model. Scanned PDFs need OCR first.

RECORD & PROVENANCE